Figure 5.

12,13-diHOME treatment reduced global chromatin accessibility specifically targeting interferon-response elements. (a) Compared to control (DMSO) exposure, human monocyte-derived macrophages exhibit a highly consistent number of chromatin accessibility regions impacted by exposure to 12,13-diHOME (50 μM for 24 hr). Significance assessed using a two-sided F-test. (b) Numbers of chromatin accessibility regions that were present in all samples (CPM > 1) treated with either vehicle (DMSO; gray) or 12,13-diHOME (50 μM for 24 hr) (orange). (c) Heatmap of the 49 regions present in 12,13-diHOME or vehicle-treated groups (detailed genomic annotations for all 49 regions are described in Supplementary table 2). Red box highlights the six regions that were present in all 12,13-diHOME-treated samples but absent in all vehicle-treated samples. (d) Four transcription factor binding sites (TFBSs) were exclusively identified 83 in the vehicle-treated samples indicating that they are inaccessible in the 12,13-diHOME treated samples. (magenta; vehicle; FDR-adjusted p < 0.05); all open areas of open chromatin were used as background (black; all).